Introduction
Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors. React in vivo, binding to and causing crosslinking of DNA which ultimately triggers apoptosis (programmed cell death). 1, 2 Cisplatin is administered intravenously as short-term infusion in physiological saline for treatment of solid malignancies and its dose should be limited by their nephrotoxicity [3] [4] [5] [6] [7] [8] [9] and other toxicities such as neurotoxicity, nausea and vomiting, ototoxicity, alopecia, electrolyte disturbance. 10 In pharmacokinetic study, cisplatin is bound to plasma proteins, enters tissues and is slowly excreted in urine with a t½ about 72 hours. Negligible amount enter brain. 11 The cisplatin concentration in proximal tubular epithelial cells is about 5 times more the serum concentration. 12 The disproportionate accumulation of cisplatin in kidney tissue contributes to cisplatin-induced nephrotoxicity. 13 Cisplatin is conjugated to glutathione and then metabolized through a rglutamy l transpeptidase and a cysteine S-conjugateb yase-dependent pathways to a eactive thiol, a potent nephrotoxin-glutamy l transpeptidase is located on the cell surface, whereas cysteine S-conjugateb yase is an intracellular enzyme. Cisplatin can form monohydrated complexes by hydrolytic reactions. The monohydrated complex is more toxic to the renal cells than cisplatin but it is not kidney specific. The normal low intracellular chloride concentrations promote its formation.
Hospital, Enayetpur, Sirajgonj, Pharmacology Research Lab., Department of Pharmacology, BSMMU, Shahbag, Dhaka From January 2012 to December 2014. A total 50 adult male (age 18-60 years) hospital admitted cancer patients receiving cisplatin were selected for this study. Smoker, alcoholic, female and CVD (cerebrovascular disease) patients were be excluded from this study. Fifty patients were taken for experiment and these patients had been received cisplatin (60-100 mg/m2) as single drug with intravenous constant infusion for 90 min. Blood and urine samples was taken at about five points per patient (at 0, ) after 3,6,12 and 24 hours.
Chromatographic conditions:
The HPLC-UV diodearray system consisted of Agilent model 1200 series degasser, solvent delivery pump, autosampler, column oven, photo diode array detector. Chromatographic data were collected and analyzed using Chemstatin software. A reverse-phase high performance liquid chromatography ( HPLC) was used for the determination of cisplatin and its metabolites in plasma and corresponding urine of 40 patients at different time interval (0, 3, 6, 12 and 24 hours). The chromatographic analyses were performed on an Agilent 5µm C18 column (150 x 4.6 mm). The mobile phase used for analysis consisted of 20% acetonitril (HPLC grade, E. Mark, Germany) and 80% distilled water and the flow rate was 0.5 ml/min. Separation was achieved at 40°C. The wave length was set at 213 nm (bandwidth 1 nm). Injection of sample (20µl) was done using an autosampler. The peak with retention time and areas were defined using software. This is for the quantitative analysis of the drug in ultra filtrate plasma and urine in the presence of nickel chloride as internal standard. Here nickel chloride will be used as internal standard.
Sample collection and preparation of Blood and Urine
Patient blood: A total 250 blood samples of 50 patients was taken for this experiment. Blood samples were taken at about five points per patient. Blood samples were collected at various time points (0, after 1hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours and 48 hours) after the end of each infusion. 5 ml x 5= 25 ml blood sample was collected from each patient at different time interval (at 0,3,6,12 & 24 hours). After complete mixing of samples with internal standard, 5 ml of ethyl acetate and vortex mixed for 2 minutes, then centrifuged at 3000 rpm for 15 minutes. 20 µL aliquots of the supernatant will be directly injected into the chromatography column. Each sample will be analyzed in duplicate. All samples or standard solutions will be stored at -5ºC until analyzed.
Patient urine:
The urine of a cancer patient was collected after receiving intravenous chemotherapy with cisplatin (60-100mg/m2) drug (0, after 3 hours, 6 hours, 12 hours, 24 hours) respectively. The urine was frozen instantly after collection. For measurement, the urine was diluted in ultrapure water (factor 20).
Determining the amount of cisplatin and their possible metabolites in plasma and urine: Determine the relative peak areas and correct for the molar detection responses of the individual components. Using the known concentration of the internal standard, calculate the concentration of those components present in the plasma and urine. The structures of the compounds will be elucidated by mass spectrometry.
Isolation and preparation of cisplatin and its metabolites from urine samples: Separation of cisplatin and its possible metabolites from urine samples of 5 patients and their primary screening for cytotoxicity. Total 20 urine samples of 5 cisplatin treated patients at 3 hr, 6 hr, 12 hr and 24 hr respectively. Each sample consists of 150 ml urine. Evaporation of water was done by rotary evaporator to dryness of the samples. Weight of dried 20 urine samples and preserved for column chromatography.
Column chromatography preparation: Each sample dissolved in 10 ml methanol and mixed with column grade silica gel and dry in air. The glass column, specially burette (35 x 1.5 cm) was packed with silica gel (Kieselgel 60, mesh 70-230). When the desired height of adsorbent bed was obtained, a few hundred milliliter of di-chloromethane was run through the column for proper packing of the column. The sample was prepared by adsorbing 2 g of dried urine sample dissolved in 1 ml methanol and applied onto silica gel, allowed to dry and subsequently applied on the top of the adsorbent layer. The column was then eluted with dichloromethane, mixtures of di-chloromethane and chloroform, chloroform-ethyl acetate and ethyl acetate with methanol then methanol with increasing polarity. Primarily 412 samples of 5 ml each were collected from 25 urine samples. After TLC (Thin layer chromatography) analysis, the fractions with similar TLC pattern were recombined and finally seventy three (73) samples were obtained.
Prepared Thin Layer Chromatograpy of collected fractions:
(Solvent system: chloroform and ethyl acetate in different polarity). PTLC of 73 [Illustration 1] fractions was done. All the column fractions were screened by TLC under UV light and spraying vanillin-sulfuric acid reagent. Mixing the same fraction due to same PTLC character to give rise to 8 fractions (23.9 mg, 27.1 mg, 22.6 mg, 21.3 mg, 19.8 mg, 20.4 mg, 18.7 mg and 17.5 mg) containing probable single compound with some impurities in each fractions. Cisplatin 100 µg/ml was used as Standard solution. These final 8 fractions were placed in glass chromatography for elucidating single compounds and identified these compounds under UV light and scratch them and dissolved in methanol and collected in small beaker. Four percent (n=2), 8% (n=4) and 20% (n=10) of total cancer patients were suffered from severe to moderate to mild hyperureamia respectively indicating strong involvement of renal system of cisplatin toxicity (figure I). 
Illustration 1: A few photographs in PTLC of 73 samples

Discussion
Cisplatin, the most widely used chemotherapeutic agents for the treatment of several human malignancies causing severe nephrotixicity. Moderate increased of serum creatinine (µg/dl), blood urea (µg/dl) and urea levels were found as 28% (n=14) and 20% (n=10) of the total patients respectively, strongly suggesting that cisplatin or its metabolites produced nephrotoxicities (Table I & II) . After continuous infusion of cisplatin (50mg-100mg diluted in 500 normal saline) over 3 hours among 50 patients, statistical analysis from data of HPLC reported that mean plasma concentration of cisplatin after 3 hours was 428.32 µg/dl (±6.092) which was sharply decreased to 3.6 µg/dl (±4.28) after 6 hours possibly due to rapid accumulation of drug in target organs and also unchanged excretion of cisplatin (which proves the previous research work). 9 Then it was gradually increased followed by decreased to 281.46 µg/dl (±1.88) and 241.98 (±231.96) after 12 and 24 hours respectively (Figure2-5). Corresponding mean urinary concentration was lowest 2.9 µg/dl (±3.15) and 1.68 µg/dl (±1.9) after 3 and 6 hours then rapidly increased to 996. 56µg/dl (±1.97) followed by slight decreased to 978.93 µg/dl (±1288.81) after 12 and 24 hours respectively due to excretion of cisplatin. So it could be reported that the highest mean plasma concentration of cisplatin was found 428.32 µg/dl (±6.092) after 3 hours and figure 18-19) . A marked number of 50 patients were suffered from moderate to severe nephrotoxicities followed cisplatin administration (increased serum creatinine level in 28% of the patients, albuminurea in 16% patients and increased blood urea levels in 20%) which correlate theprevious research work. 11-13 Separation of cisplatin and its possible metabolites from urine samples of 5 patients was done by using column chromatography, glass chromatography, PTLC using a range of solvent systems with different polarity and finally their Rf values were done (Table I & Photograph 1) .
Conclusion
Present study revealed that the metabolites were found more toxic than cisplatin. So, further study will be designed to identified whether the cisplatin or its metabolites causes nephrotoxicity in cancer patients.
